当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?

Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?

Abstract：

:The Cleveland Clinic blood and marrow transplant program has routinely performed 'backup' autologous harvests in unrelated recipients with hematological malignancies in remission, lymphoma without marrow involvement and CML in chronic phase. We reviewed all adult or cord unrelated donor (URD) transplants performed from January 1995 through September 2008 to evaluate the value of this procedure. Of 130 patients who had backup harvests, 15 (11%) had their backup harvests re-infused, all for graft failure. No patients undergoing fully ablative preparation and unmanipulated or T-depleted grafts from well-matched adult donors required infusion of backup marrow. Nine of 42 patients who underwent T cell grafts from partially matched or mismatched donors, five patients undergoing partially matched ablative transplants from adult donors or cord blood, and one patient undergoing non-myeloablative transplant required infusion of their back-up harvest. Five of 15 patients who received their backup marrow are alive in CR 2-11.6 (median 7.6) years from infusion. Two of these five were bridged to a second URD transplant; the other three showed durable disease-free survival without a second allogeneic transplant. Backup harvest is unnecessary for HLA well-matched myeloablative transplants, but may be useful in patients at higher risk of graft failure.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Stotler C,Bolwell B,Sobecks R,Dean R,Serafino S,Rybicki L,Andresen S,Pohlman B,Kalaycio M,Copelan E

doi

10.1038/bmt.2009.95

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

49-52

issue

1

eissn

0268-3369

issn

1476-5365

pii

bmt200995

journal_volume

45

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.

    abstract：:We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

    更新日期：1994-10-01 00:00:00

  • Evaluation of remission state in chronic myeloid leukemia patients after bone marrow transplantation using cytogenetic and molecular genetic approaches.

    abstract：:The remission state of 13 Philadelphia positive chronic myeloid leukemia patients was studied after bone marrow transplantation (BMT) by cytogenetic and Southern blot analysis of the breakpoint cluster region (BCR) gene. Eight of 13 patients showed neither clinical nor genetic evidence of residual disease. In two pati...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Arnold R,Bartram CR,Heinze B,Carbonell F,Wiesneth M,Hertenstein B,Schmeiser T,Heit W,Kubanek B,Heimpel H

    更新日期：1989-07-01 00:00:00

  • Absence of IL-23p19 in donor allogeneic cells reduces mortality from acute GVHD.

    abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.215

    authors： Thompson JS,Chu Y,Glass JF,Brown SA

    更新日期：2010-04-01 00:00:00

  • Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD.

    abstract：:Extracorporeal photopheresis (ECP) is beneficial in patients with T-cell-mediated disorders, including GvHD, but the underlying immunological mechanisms are incompletely understood. Myeloid-derived suppressor cells (MDSCs) are innate immune cells characterized by their capacity to suppress T-cell proliferation. We qua...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.236

    authors： Rieber N,Wecker I,Neri D,Fuchs K,Schäfer I,Brand A,Pfeiffer M,Lang P,Bethge W,Amon O,Handgretinger R,Hartl D

    更新日期：2014-04-01 00:00:00

  • Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.

    abstract：:In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b in...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Lo Coco F,Mandelli F,Diverio D,Alimena G,De Fabritiis P,Meloni G,Cedrone M,Frontani M,Guerrasio A,Saglio G

    更新日期：1990-10-01 00:00:00

  • Biological characterization of CD34+ cells mobilized into peripheral blood.

    abstract：:We review here the functional and kinetic characteristics of highly purified hematopoietic CD34+ mobilized into peripheral blood (PB) by granulocyte colony-stimulating factor (G-CSF) with or without chemotherapy for autologous or allogeneic transplantation. Circulating CD34+ cells were evaluated for their colony-formi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Lemoli RM,Tafuri A,Fortuna A,Catani L,Rondelli D,Ratta M,Tura S

    更新日期：1998-12-01 00:00:00

  • Influence of HLA-DPB1 mismatches on MLR responses: the role of high resolution HLA class II typing and MLC in unrelated donor selection for BMT.

    abstract：:Twenty eight Hungarian patients lacking a compatible related donor and their 61 HLA-A,B,DR serologically identical potential unrelated donors (selected from BMDW) were investigated in this study. Out of the 61 donor-recipient pairs only 7 (11,5%) proved to be HLA-identical at DNA level. Thirty one pairs (50,8%) differ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Pénzes M,Rajczy K,Gyódi E,Petrányi GG

    更新日期：1998-12-01 00:00:00

  • Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.

    abstract：:Acute graft-versus-host disease (GVHD) is the most important complication of allogeneic bone marrow transplantation. We investigated the possibility of predicting severe acute GVHD using plasma interleukin-10 levels in 31 patients who underwent allogeneic bone marrow transplantation. In patients with acute GVHD, the i...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702010

    authors： Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Yamada S,Kanamaru A,Kakishita E

    更新日期：1999-11-01 00:00:00

  • Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey.

    abstract：:We report the experience of 14 centers which have used the combination of cytosine arabinoside (ara-C; 24-36 g/m2) and total body irradiation (TBI) to prepare 213 patients with acute lymphoblastic leukemia (ALL) for allogeneic BMT. The overall 3-year disease-free survival (DFS) probability is 38% (95% CI: 31-45%); 75 ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Weyman C,Graham-Pole J,Emerson S,August C,Champlin R,Coccia P,Fay J,Harris R,Koch P,Johnson L

    更新日期：1993-01-01 00:00:00

  • Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.

    abstract：:A retrospective comparison was carried out on adult patients receiving HLA-identical allogeneic haemopoietic stem cell transplants from siblings in Australia in 1996, comparing bone marrow with G-CSF-mobilised peripheral blood stem cells. A total of 131 transplant recipients from nine centres were included in this stu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1703088

    authors： Nivison-Smith I,Bradstock KF,Szer J,Durrant S,Dodds A,Hermann R,Schwarer AP,Gibson J,To LB,Arthur C,Australian Bone Marrow Transplant Cooperative Sutdy Group.

    更新日期：2001-07-01 00:00:00

  • Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.

    abstract：:Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) may be associated with a reduced risk of infection compared to standard allogeneic HCT. We retrospectively analyzed incidence and risk factors of infection in 62 patients undergoing NMSCT with low-dose TBI +/- fludarabine and post...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705255

    authors： Frère P,Baron F,Bonnet C,Hafraoui K,Pereira M,Willems E,Fillet G,Beguin Y

    更新日期：2006-02-01 00:00:00

  • Introduction: current issues in high-dose chemotherapy and stem cell support.

    abstract：:In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support high-dose chemotherapy procedures in patients ot...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1701667

    authors： Shea TC

    更新日期：1999-05-01 00:00:00

  • Characterization of CD34+ subsets derived from bone marrow, umbilical cord blood and mobilized peripheral blood after stem cell factor and interleukin 3 stimulation.

    abstract：:We characterized CD34+ cells purified from bone marrow (BM), mobilized peripheral blood (PB) and cord blood (CB) and we tried to establish correlations between the cell cycle kinetics of the CD34+CD38- and CD34+CD38+ subpopulations, their sensitivity to SCF and IL-3 and their expression of receptors for these two CSFs...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702145

    authors： De Bruyn C,Delforge A,Lagneaux L,Bron D

    更新日期：2000-02-01 00:00:00

  • Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

    abstract：:Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma p...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0298-y

    authors： Schechter T,Perez-Albuerne E,Lin TF,Irwin MS,Essa M,Desai AV,Frangoul H,Yanik G,Dupuis LL,Jacobsohn D,Kletzel M,Ranalli M,Soni S,Seif AE,Grupp S,Dvorak CC

    更新日期：2020-03-01 00:00:00

  • Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.

    abstract：:Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, p...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704621

    authors： Anderlini P,Acholonu SA,Okoroji GJ,Andersson BS,Couriel DR,De Lima MJ,Donato ML,Khouri IF,Giralt SA,Ueno NT,Champlin RE

    更新日期：2004-09-01 00:00:00

  • Virus recovery from stools of patients undergoing bone marrow transplantation.

    abstract：:Diarrhea in marrow transplant recipients is a frequent complication attributable to non-infectious events such as acute GVHD or infectious events such as viral gastroenteritis. Rotavirus and enteric adenovirus are the most frequent viral pathogens. To determine the frequency of these infections, we prospectively exami...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Troussard X,Bauduer F,Gallet E,Freymuth F,Boutard P,Ballet JJ,Reman O,Leporrier M

    更新日期：1993-12-01 00:00:00

  • Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT.

    abstract：:CTLA-4 is a negative regulator of activated T cells and the association of CTLA-4 polymorphisms with autoimmune diseases and transplant outcome has been reported. We evaluated the effect of donor CTLA-4 polymorphisms on outcome after allogeneic hematopoietic SCT (HSCT). We analyzed 147 Japanese HLA-matched sibling rec...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.319

    authors： Murase M,Nishida T,Onizuka M,Inamoto Y,Sugimoto K,Imahashi N,Murata M,Miyamura K,Kodera Y,Inoko H,Naoe T

    更新日期：2011-11-01 00:00:00

  • Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus.

    abstract：:Our previous data have revealed that proteinuria, antinuclear antibodies and anti-dsDNA antibodies in refractory systemic lupus erythematosus (SLE) reduced after MSC infusion. This study focused on the roles of mesenchymal SCT (MSCT) in SLE patients with refractory cytopenia. Thirty-five SLE patients with refractory c...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2012.184

    authors： Li X,Wang D,Liang J,Zhang H,Sun L

    更新日期：2013-04-01 00:00:00

  • Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.

    abstract：:We prospectively studied absolute lymphocyte (ALC) and monocyte counts (AMC), lymphocyte subsets and proliferative in vitro responses to mitogen and antigen in 12 patients with AL-amyloidosis (AL) undergoing autologous blood stem cell transplantation (SCT) with high-dose i.v. melphalan. Myeloid and lymphoid recovery (...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703298

    authors： Akpek G,Lenz G,Lee SM,Sanchorawala V,Wright DG,Colarusso T,Waraska K,Lerner A,Vosburgh E,Skinner M,Comenzo RL

    更新日期：2001-12-01 00:00:00

  • Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia.

    abstract：:Seventeen patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) were treated with the ICE regimen plus G-CSF with the aim of mobilizing and collecting Ph-negative peripheral stem cells (PSC) in the setting of an autotransplant program. Fifteen patients had CML in first chronic phase (CP), ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Boqué C,Petit J,Sarrá J,Cancelas JA,Muñoz J,Español JI,de la Banda E,Aventin A,Berlanga J,Ferrá C,Amill B,Torrico C,Azqueta C,Llucià M,García J,Grañena A

    更新日期：1996-11-01 00:00:00

  • Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.

    abstract：:Over the last 15 years, we have performed a total of 30 haematopoietic stem cell transplants on 27 children suffering from Hurler's syndrome. These children were of median age 11 months at the time of diagnosis and 25 months at the time of transplantation. The phenotype was severe in 21 cases (78%). The donor was fami...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704105

    authors： Souillet G,Guffon N,Maire I,Pujol M,Taylor P,Sevin F,Bleyzac N,Mulier C,Durin A,Kebaili K,Galambrun C,Bertrand Y,Froissart R,Dorche C,Gebuhrer L,Garin C,Berard J,Guibaud P

    更新日期：2003-06-01 00:00:00

  • Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease).

    abstract：:Congenital erythropoietic porphyria (Gunther's disease, GD) is a rare autosomal recessive disease. It results from the deficiency of uroporphyrinogen III synthase, the fourth enzyme on the metabolic pathway of heme synthesis. GD leads to severe scarring of the face and hands as a result of photosensitivity and fragili...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Zix-Kieffer I,Langer B,Eyer D,Acar G,Racadot E,Schlaeder G,Oberlin F,Lutz P

    更新日期：1996-07-01 00:00:00

  • Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.

    abstract：:Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

    更新日期：1994-12-01 00:00:00

  • Effect of in vivo therapy with a CD8 monoclonal antibody on delayed engraftment after autologous bone marrow transplantation.

    abstract：:Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+,...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Favrot M,Philip T,Combaret V,Lemerle J,Marie JP,Bernard A

    更新日期：1990-01-01 00:00:00

  • Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

    abstract：:Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-019-0536-y

    authors： Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

    更新日期：2019-11-01 00:00:00

  • Induction of graft-versus-host disease and a graft-versus-leukemia effect using ubenimex in a patient with infantile leukemia relapsing after an unrelated cord blood transplant.

    abstract：:A 20-month-old boy with infantile leukemia was treated with total body irradiation, etoposide, cyclophosphamide and unrelated cord blood transplantation with a one-antigen mismatch. He relapsed on day 100 and achieved remission after ubenimex administration, and also developed chronic graft-versus-host disease of the ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703679

    authors： Okada H,Nomi K,Hamatani S,Kuromi T,Nanba M,Imai T,Isobe K,Itoh S

    更新日期：2002-10-01 00:00:00

  • Various patterns of chimerism after allogeneic bone marrow transplantation for advanced chronic lymphocytic leukemia.

    abstract：:Chimerism studies after allogeneic BMT are performed to determine the donor and/or recipient origin of peripheral blood and marrow lymphoid and hematopoietic cells. These studies have been performed mostly in leukemias and aplastic anemia. We report DNA-based chimerism studies in three patients transplanted for advanc...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Martino R,Brunet S,García A,Sureda A,Soler J,Martínez C,Domingo-Albós A,Baiget M

    更新日期：1995-12-01 00:00:00

  • HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.

    abstract：:HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 1...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1705315

    authors： Ho VT,Kim HT,Liney D,Milford E,Gribben J,Cutler C,Lee SJ,Antin JH,Soiffer RJ,Alyea EP

    更新日期：2006-05-01 00:00:00

  • Sixty as the new forty: considerations on older related stem cell donors.

    abstract：:The era of reduced-intensity allogeneic stem cell transplantation, with its emphasis on older patients, has created new challenges in the management of what is now an older related stem cell donor population. These donors are now on average no less than 10 years older than in the mid-1990s. Donors over 70 years of age...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2016.201

    authors： Anderlini P

    更新日期：2017-01-01 00:00:00

  • Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.

    abstract：:Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/sj.bmt.1705935

    authors： Biron P,Durand M,Roché H,Delozier T,Battista C,Fargeot P,Spaeth D,Bachelot T,Poiget E,Monnot F,Tanguy ML,Curé H

    更新日期：2008-03-01 00:00:00